SCHEMBL353036

SCHEMBL353036

O=C(/C=C/C(=O)OCC1CNCCO1)OCC1CNCCO1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.41
SLC6A4 P31645 4/20 0.41
SLC6A2 P23975 2/20 0.41
HTR2B P41595 2/20 0.41
SLC6A3 Q01959 2/20 0.41
ADRB2 P07550 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA2C P18825 1/20 0.41
MGLL Q99685 2/20 0.40
HRH1 P35367 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
HTR3A P46098 1/20 0.36
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
IRAK4 Q9NWZ3 6/20 0.34
CHEK1 O14757 1/20 0.34
FECH P22830 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353038 1.00 HTR2A (0.41) HTR2ASLC6A4SLC6A2HTR2BSLC6A3
SCHEMBL351289 1.00 HTR2A (0.41) HTR2ASLC6A4SLC6A2HTR2BSLC6A3
SCHEMBL352366 1.00 HTR2A (0.41) HTR2ASLC6A4SLC6A2HTR2BSLC6A3
SCHEMBL15444487 0.87 HTR2A (0.40) HTR2ASLC6A4SLC6A2HTR2BSLC6A3
SCHEMBL351295 0.84 HTR2A (0.44) HTR2ASLC6A4SLC6A2HTR2BSLC6A3
SCHEMBL352320 0.84 HTR2A (0.44) HTR2ASLC6A4SLC6A2HTR2BSLC6A3
SCHEMBL31268264 0.81 ADRA2C (0.46) HTR2ASLC6A4SLC6A2HTR2BSLC6A3
SCHEMBL13003640 0.81 SLC6A4 (0.46) HTR2ASLC6A4SLC6A2HTR2BSLC6A3
SCHEMBL31373415 0.81 ADRA2C (0.46) HTR2ASLC6A4SLC6A2HTR2BSLC6A3
SCHEMBL27906798 0.81 ADRA2C (0.46) HTR2ASLC6A4SLC6A2HTR2BSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648190-B2 Process for producing 2-hydroxymethylmorpholine salt DAISO CO., LTD. (JP) 2014-02-11 US disclosed
EP-2388252-B1 PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT DAISO CO LTD (JP) 2013-07-24 EP disclosed
US-20120016120-A1 PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT DAISO CO., LTD. (JP) 2012-01-19 US disclosed
EP-2388252-A1 PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT Daiso Co., Ltd. (JP) 2011-11-23 EP disclosed
US-8040010-B2 Permanent magnet type generator and hybrid vehicle using the same HITACHI, LTD. (JP) 2011-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016120-A1 PROCESS FOR PRODUCING 2-HYDROXYMETHYLMORPHOLINE SALT THOP1, AVPR2, HPD HTR2A 16/4885SLC6A4 111/4885SLC6A2 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.